According to data compiled by Bloomberg, in 2018 Canadian weed companies triggered $12.8 billion in takeovers & acquisitions and $4.3 billion in financings.
There were some smart deals done like LiveWell (LVWL.V)’s acquisition of of Vitality CBD Natural Health Products and iAnthus Capital (IAN.C)‘s $835 million all-stock transaction to “combine with MPX” – and a couple of head scratchers.
“You’re seeing massive amounts of M&A over the last six months,” confirmed Dan Nicholls, director of Capital Markets Advisory Services at ELLO in an excellent Cannabis Business Times interview, “It’s really just companies trying to scale up and build market share as fast as possible.”
“One of the most important things to do in M&A is identify the value drivers,” continued Nicholls, “If Company A is buying Company B, why are they doing the deal? It’s good to identify three, four or five key reasons why they’re doing the deal.”
One of those “key reasons” is price.
You buy something because a. you want it and b. you think it’s a good deal.
In the last 3 months, the Canadian Marijuana Index has lost almost half its value – falling from 869 to 461.
Rapidly falling valuations make it harder to get a deal done. Example: Let’s say you were planning to buy Namaste (N.V) 3 months ago. The stock was trading at $3.74 and the company had a market cap of $1.15 billion.
Amped-up by CEO Sean Dollinger’s bullish growth projections – you agree to pay a 30% premium to market – about $1.5 billion in total.
As your M&A team does due diligence, and the purchase agreement bounces back and forth between legal teams, Namaste share price slides hard. Three months later, the stock is trading at $1.02 with a market cap of $313 million.
Suddenly that $1.5 billion Namaste price tag seems…a little rich.
You: “We are not going to pay $1.5 billion for an asset worth $313 million!”
Namaste: “But you said you would!”
As the investment community sours on the weed sector, some of these proposed mergers are starting to go sideways.
On November 05, 2018 Golden Leaf (GLH.C) and Terra Tech (TRTC.OTC) announced a mutual intent to merge into a single cultivation, production and retail operation built around recognized brands.
The LOI stated that Golden Leaf shareholders will receive .1203 shares of Terra Tech for each Golden Leaf share – creating a combined company that will control 41 permits across cultivation, manufacturing, distribution and retail spanning Oregon, California and Nevada.
Six weeks later, GLH had lost 45% of its value, while TRTC had shed 70% of its value.
On December 18, 2018, GLH issued a terse press release stating that it has “decided not to pursue a potential transaction with Terra Tech.” In the 48 hours following the aborted deal, Terra Tech’s share price spiked 30%, while Golden Leaf’s drifted down 8%.
When the goal posts move (valuations change) sometimes – if both parties are flexible – a calm re-negotiation can save a deal.
Example: On December 3, 2019 GLH announced that it had “favorably restructured the deal terms” with Tahoe Hydroponics.
The original agreement valued the acquisition at $52.4 million consisting of $11.1 million in cash and shares worth $41.3 million. The reworked deal calls for “Issuance of GLH common stock equivalent to $16.2 million and a “two-part earn-out provision.”
Perhaps not coincidentally, both companies shed 40% of their respective market caps in the previous 3 months. In a stock transaction, if one company dives while the other spikes during due diligence – it incentivises the rising company to kill the deal.
Despite the challenging landscape, consolidations are still getting done.
On December 19, 2018 Aleafia Health (ALEF.V) announced that it will be buying Emblem Corp (EMC.V) in “an all-stock deal worth $173 million” to create “the largest network of medical cannabis clinics across Canada.”
Royal Bank of Canada’s investment-banking division, RBC Capital Markets recently announced that it will participate in “arranging takeovers for companies in the marijuana industry.”
“We were being careful around cannabis,” admitted an RBC spokesperson, “It’s safety first here.”
The lesson for cannabis investors is: “Do not bake announced mergers into your investing decisions until those mergers are consummated”.
Cannabis companies are “all technically start-ups,” observed the M&A expert Nicholls. “Even some of these billion-dollar companies. And when it comes to buying start-ups, it’s a whole different can of worms.”
Before GLH bailed on the deal with TRTC, it warned shareholders that “Consummation of the transaction is subject to a number of conditions.”
“If you agreed to do a deal for shares at $0.30 and the price is now $0.14, you’re definitely going to have some discussions,” stated Equity Guru’s Chris Parry on a company back channel.
Full Disclosure: Emblem used to be an Equity Guru marketing client. LiveWell still is. We also own stock in LiveWell. We have no commercial relationship with the other companies mentioned in the article.Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Lukas Kane (see all)
- Hemptown USA unveils CBG product line at massive Las Vegas MJ conference - December 11, 2019
- 95 million Americans do not receive a paycheck – does that matter? - December 10, 2019
- Merck (MRK.NASDAQ), Sanofi (SNY.NASDQ) – is Big Pharma a cancer? - December 9, 2019